The DiviTum® TKa Blood Test: Monitoring Disease Progression
Studies in multiple cancers demonstrate that cancer cells release high levels of thymidine kinase (TK) into the bloodstream. Biovica’s DiviTum® TKa blood-based biomarker test measures TK activity (TKa), a marker of cell proliferation. Patients with high levels of TK activity in their blood have a worse prognosis and a high likelihood of progression. In the same way, patients with lower TKa have been shown to be associated with a low likelihood of imminent disease progression.
The DiviTum TKa test is FDA-cleared and is used as an aid in monitoring disease progression by measuring the level of TK activity. The DiviTum TKa test is performed at Biovica’s CLIA-certified laboratory in San Diego.